3 Sulfas Injectable

3 SULFAS is an injectable solution made with Sulfamethazine, Sulfamerazine, and Sulfadiazine, whose antibiotic combination offers greater solubility, lower renal toxicity, and a broader antibacterial spectrum of action against gram-positive and gram-negative bacteria that cause digestive, respiratory, genitourinary, mammary gland, musculoskeletal, and septicemic diseases in cattle, horses, sheep, pigs, poultry, and dogs.

Antibiotic
Sulfamethazine, sulfamerazine, and sulfadiazine

MECHANISM OF ACTION: 3 SULFAS have a mechanism of action based on occupying para-aminobenzoic acid (PABA) receptors, preventing bacteria from incorporating folic acid and the growth factors they require and cannot synthesize into their metabolism. Additionally, they inhibit aerobic and anaerobic bacterial respiration.

PHARMACOKINETICS

When 3 SULFAS are administered parenterally or orally, they show excellent absorption. They enter the bloodstream, are distributed throughout the body, and bind to plasma albumin, rapidly diffusing to reach high concentrations in extravascular fluids, allowing them to eliminate bacterial infections, most of which are extravascular. They also diffuse easily into the fetus and fetal membranes, showing lower concentrations in the central nervous system, bones, and adipose tissue. They are metabolized in the liver and excreted by glomerular filtration and tubular secretion in the kidneys, with smaller amounts eliminated in feces, bile, pancreatic juice, gastric juice, saliva, and milk.

IMPORTANCE

The importance of 3 SULFAS lies in the combination of the contained SULFAS, which provides greater solubility, better absorption, lower renal toxic effect, and a broader antibacterial spectrum of action against gram-positive and gram-negative bacteria that cause digestive, respiratory, genitourinary, mammary gland, musculoskeletal, and septicemic diseases in cattle, horses, sheep, pigs, poultry, and dogs.

INDICATIONS

3 SULFAS are indicated for the treatment of respiratory tract infections (pneumonia, bronchopneumonia, etc.), gastrointestinal tract infections (colibacillosis), upper and lower urinary tract infections, genital tract infections (septic metritis, retained placenta), musculoskeletal system infections (foot rot), mammary gland infections (acute and chronic mastitis), and other infections affecting cattle, sheep, goats, swine (hemorrhagic septicemia, necrotic enteritis), canines (pneumonia, bacillary diarrhea, and complications of canine distemper), and poultry (coccidiosis, salmonellosis, and fowl cholera).

ADMINISTRATION ROUTE AND DOSAGE:

• Intravenous: In cattle, horses, sheep, goats, and dogs.
• Intramuscular: In pigs
• Oral in drinking water: In poultry

The dose depends on the specific case; however, in general terms, the recommended dose is:

• Horses and Cattle: 50 mL of 3 SULFAS per 100 kg intravenously (100 mg/kg of weight).
• Pigs, Sheep, and Goats: 7 mL of 3 SULFAS per 10 kg (140 mg/kg of weight).
• In Dogs and Cats: 3.5 to 7 mL of 3 SULFAS per 10 kg via slow intravenous injection (70 - 140 mg per kg of weight).
• In poultry, the dose will depend on the administration route: Intramuscular: 0.5 mL of 3 SULFAS per 1 kg. Drinking water: 5 mL of 3 SULFAS per liter of drinking water for 2 to 3 days of treatment, followed by a break of 2 to 3 days and repeating the administration for 2 to 3 more days. Respiratory problems: 100 mg/kg. Digestive problems: 50 mg/kg of weight.

CONTRAINDICATIONS

Should not be used in animals showing liver damage, kidney damage, blood dyscrasias, or a history of hypersensitivity to sulfonamides.

Do not use in horses intended for human consumption. Due to its potential to crystallize urine, it is advisable to avoid its use in dogs with a history of urolithiasis or at high risk of developing urolithiasis.

ADVERSE EFFECTS

In dogs, keratoconjunctivitis sicca (which may not be reversible), acute neutrophilic hepatitis, anorexia, diarrhea, fever, hemolytic anemia, urticaria, polyarthritis, facial swelling, polydipsia, polyuria, and cholestasis may occur. Potentiated sulfonamides can cause hypothyroidism in dogs, particularly with extended therapies. Acute type I or type II hypersensitivity reactions may occur in rare cases. Other hematological effects (anemia, agranulocytosis) are possible but very rare. Adverse effects in cats may include anorexia, leukopenia, and anemia. In horses, transient pruritus may occur after intravenous administration.

OVERDOSAGE

Manifestations of overdose may include gastrointestinal clinical signs (nausea, vomiting, diarrhea), CNS toxicity (depression, headache, and confusion), facial swelling, bone marrow aplasia, and increased serum aminotransferases. Blood cell counts should be constantly monitored.

DRUG INTERACTIONS

The use of antacids may decrease the bioavailability of sulfonamides if administered concomitantly. Concomitant cyclosporine may increase the risk of toxicity. The use of diuretics may increase the risk of thrombocytopenia.

Sulfonamides can displace methotrexate from plasma proteins and increase the risk of toxic effects. Sulfonamides can prolong the half-life of phenytoin. Sulfonamides can decrease the effectiveness of tricyclic antidepressants. Sulfonamides can prolong INR/PT times when used with warfarin.

WARNINGS

This product is for exclusive use in veterinary medicine; do not use in humans. Store at a temperature below 25°C and protected from sunlight. Keep out of reach of children.

WITHDRAWAL PERIOD: 5 days for meat and milk.

PRESENTATION: 100, 250, and 500 ml bottles.

FORMULA:

Each 100 mL contains:

Sulfamethazine: 6.66 g, Sulfamerazine: 6.66 g Sulfadiazine: 6.66 g, Sterile distilled water q.s.p: 100.00 ml